评估血清可溶性ST2作为癌症相关静脉血栓栓塞的诊断生物标志物的作用

IF 1.8 Q3 HEMATOLOGY

Hematology, Transfusion and Cell Therapy Pub Date : 2025-01-01 DOI:10.1016/j.htct.2025.103740

Eman Mohamed Abdellatif, Emad Hamdy Hamouda Mohammed, Azza Mohamed Amin Darwish

{"title":"评估血清可溶性ST2作为癌症相关静脉血栓栓塞的诊断生物标志物的作用","authors":"Eman Mohamed Abdellatif, Emad Hamdy Hamouda Mohammed, Azza Mohamed Amin Darwish","doi":"10.1016/j.htct.2025.103740","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Venous thromboembolism, a common complication associated with cancer, causes increased morbidity and mortality. D-dimer levels are often increased non-specifically in cancer which limits their use to diagnose venous thromboembolism. The current study aimed to investigate the role of the serum soluble suppression of tumorigenicity 2 (sST2) as a new biomarker to diagnose venous thromboembolism in cancer.</div></div><div><h3>Methods</h3><div>Eighty-eight patients with different types of cancer were enrolled and divided into two groups: Group I: 44 cancer patients with confirmed diagnosis of venous thromboembolism and Group II: 44 age- and sex-matched cancer patients without any thrombotic complications. The D-dimer test and sST2 measurement were performed for all study subjects.</div></div><div><h3>Results</h3><div>Serum sST2 levels were significantly higher in Group I than in Group II (<em>p</em>-value < 0.001); the median serum sST2 was 13.02 ng/mL (range: 7.65–117.9 ng/mL) in Group I versus 8.56 ng/mL (range: 5.59–10.33 ng/mL) in Group II. There was a significant positive correlation between serum sST2 and the D-dimer level. Using a receiver operating characteristic curve, sST2 had a greater area under the curve than the D-dimer test (0.974 versus 0.869, respectively). Although the D-dimer test was more sensitive, sST2 had a greater specificity than D-dimer (95.45 % versus 27.3 %, respectively) and a higher positive predictive value (95.3 % versus 56.8 %, respectively).</div></div><div><h3>Conclusion</h3><div>The results of the current study support a potential role of soluble ST2 to aid in diagnosing venous thromboembolism in cancer patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 1","pages":"Article 103740"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the role of serum soluble ST2 as a diagnostic biomarker for cancer-associated venous thromboembolism\",\"authors\":\"Eman Mohamed Abdellatif, Emad Hamdy Hamouda Mohammed, Azza Mohamed Amin Darwish\",\"doi\":\"10.1016/j.htct.2025.103740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Venous thromboembolism, a common complication associated with cancer, causes increased morbidity and mortality. D-dimer levels are often increased non-specifically in cancer which limits their use to diagnose venous thromboembolism. The current study aimed to investigate the role of the serum soluble suppression of tumorigenicity 2 (sST2) as a new biomarker to diagnose venous thromboembolism in cancer.</div></div><div><h3>Methods</h3><div>Eighty-eight patients with different types of cancer were enrolled and divided into two groups: Group I: 44 cancer patients with confirmed diagnosis of venous thromboembolism and Group II: 44 age- and sex-matched cancer patients without any thrombotic complications. The D-dimer test and sST2 measurement were performed for all study subjects.</div></div><div><h3>Results</h3><div>Serum sST2 levels were significantly higher in Group I than in Group II (<em>p</em>-value < 0.001); the median serum sST2 was 13.02 ng/mL (range: 7.65–117.9 ng/mL) in Group I versus 8.56 ng/mL (range: 5.59–10.33 ng/mL) in Group II. There was a significant positive correlation between serum sST2 and the D-dimer level. Using a receiver operating characteristic curve, sST2 had a greater area under the curve than the D-dimer test (0.974 versus 0.869, respectively). Although the D-dimer test was more sensitive, sST2 had a greater specificity than D-dimer (95.45 % versus 27.3 %, respectively) and a higher positive predictive value (95.3 % versus 56.8 %, respectively).</div></div><div><h3>Conclusion</h3><div>The results of the current study support a potential role of soluble ST2 to aid in diagnosing venous thromboembolism in cancer patients.</div></div>\",\"PeriodicalId\":12958,\"journal\":{\"name\":\"Hematology, Transfusion and Cell Therapy\",\"volume\":\"47 1\",\"pages\":\"Article 103740\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology, Transfusion and Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2531137925000082\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137925000082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

静脉血栓栓塞是一种与癌症相关的常见并发症，导致发病率和死亡率增加。d -二聚体水平通常在癌症中非特异性升高，这限制了其在诊断静脉血栓栓塞中的应用。本研究旨在探讨血清可溶性抑制致瘤性2 （sST2）作为诊断癌症静脉血栓栓塞的新生物标志物的作用。方法将88例不同类型的癌症患者分为两组：第一组：44例确诊为静脉血栓栓塞的癌症患者；第二组：44例年龄和性别匹配的无血栓并发症的癌症患者。对所有研究对象进行d -二聚体检验和sST2测定。结果I组血清sST2水平显著高于II组(p值<；0.001);I组血清sST2中位数为13.02 ng/mL（范围：7.65-117.9 ng/mL）， II组为8.56 ng/mL（范围：5.59-10.33 ng/mL）。血清sST2与d -二聚体水平呈正相关。使用受试者工作特征曲线，sST2的曲线下面积大于d -二聚体试验（分别为0.974和0.869）。虽然d -二聚体检测更敏感，但sST2的特异性比d -二聚体更高（分别为95.45%和27.3%），阳性预测值更高（分别为95.3%和56.8%）。结论目前的研究结果支持可溶性ST2在癌症患者静脉血栓栓塞诊断中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of the role of serum soluble ST2 as a diagnostic biomarker for cancer-associated venous thromboembolism

Introduction

Venous thromboembolism, a common complication associated with cancer, causes increased morbidity and mortality. D-dimer levels are often increased non-specifically in cancer which limits their use to diagnose venous thromboembolism. The current study aimed to investigate the role of the serum soluble suppression of tumorigenicity 2 (sST2) as a new biomarker to diagnose venous thromboembolism in cancer.

Methods

Eighty-eight patients with different types of cancer were enrolled and divided into two groups: Group I: 44 cancer patients with confirmed diagnosis of venous thromboembolism and Group II: 44 age- and sex-matched cancer patients without any thrombotic complications. The D-dimer test and sST2 measurement were performed for all study subjects.

Results

Serum sST2 levels were significantly higher in Group I than in Group II (p-value < 0.001); the median serum sST2 was 13.02 ng/mL (range: 7.65–117.9 ng/mL) in Group I versus 8.56 ng/mL (range: 5.59–10.33 ng/mL) in Group II. There was a significant positive correlation between serum sST2 and the D-dimer level. Using a receiver operating characteristic curve, sST2 had a greater area under the curve than the D-dimer test (0.974 versus 0.869, respectively). Although the D-dimer test was more sensitive, sST2 had a greater specificity than D-dimer (95.45 % versus 27.3 %, respectively) and a higher positive predictive value (95.3 % versus 56.8 %, respectively).